Research programme: decoy oligonucleotides - DOLTHERA

Drug Profile

Research programme: decoy oligonucleotides - DOLTHERA

Alternative Names: decoy ODN; ODN

Latest Information Update: 07 Mar 2011

Price : $50

At a glance

  • Originator Avontec
  • Developer DOLTHERA
  • Class Oligonucleotides
  • Mechanism of Action Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atherosclerosis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 07 Mar 2011 No development reported - Preclinical for Transplant rejection in Germany (Parenteral)
  • 07 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in Germany (Parenteral)
  • 07 Mar 2011 No development reported - Preclinical for Atherosclerosis in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top